 |
|
Suppression of Raynaud's Phenomenon by Methyldopa
David P. Varadi, MD;
A. M. Lawrence, MD
Arch Intern Med. 1969;124(1):13-18.
Abstract
By the use of thermocouple and clinical data, methyldopa was evaluated as a therapeutic agent in 42 patients with Raynaud's phenomenon. The administration of 1 to 2 gm daily of methyldopa was frequently effective in (1) preventing episodes of Raynaud's phenomenon during both experimental cold exposure and normal wintertime exposure; (2) improving the blood supply to the digital skin during cold exposure; (3) increasing the rate of rewarming of digits after cold exposure; and (4) relieving chronic pain in the fingers, which occurred at ambient temperatures above 25 C. The response of Raynaud's phenomenon to methyldopa depended most significantly on the relative contribution, in a given digit, of (1) spasm and (2) organic obstruction of digital vessels, respectively, to the development of ischemia. Only if spasm predominated could one anticipate a good response.
Author Affiliations
Toronto, Canada; Chicago
From the Department of Medicine, University of Chicago (Dr. Lawrence); and the Department of Medicine, Section of Dermatology, Wellesley Hospital, University of Toronto (Dr. Varadi). Dr. Lawrence is an American College of Physicians Teaching and Research Scholar.
Footnotes
Received for publication Nov 21, 1968; accepted Feb 25, 1969.
Reprint requests to 160 Wellesley St E, Toronto, Canada (Dr. Varadi).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Pathophysiology of Raynaud's Disease
Halperin and Coffman
Arch Intern Med 1979;139:89-92.
ABSTRACT
Physiatrics for Deforming Linear Scleroderma
Rudolph and Leyden
Arch Dermatol 1976;112:995-997.
ABSTRACT
|
